Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Panu M. Jaakkola"'
Autor:
Misba Khan, Md. Khirul Islam, Mafiur Rahman, Bert Dhondt, Ileana Quintero, Maija Puhka, Panu M. Jaakkola, Urpo Lamminmäki, Janne Leivo
Publikováno v:
Nano Select, Vol 5, Iss 9, Pp n/a-n/a (2024)
Abstract Half of patients with renal cell carcinoma (RCC) develop metastases. New and noninvasive biomarkers are needed for the diagnosis of RCC. The study aims to develop an EV‐based assay for the detection of RCC using a highly sensitive nanopart
Externí odkaz:
https://doaj.org/article/e55164b7822c462caf1219c44a7c0720
Autor:
Kalle E. Mattila, Teemu D. Laajala, Sara V. Tornberg, Tuomas P. Kilpeläinen, Paula Vainio, Otto Ettala, Peter J. Boström, Harry Nisen, Laura L. Elo, Panu M. Jaakkola
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract After surgery of localized renal cell carcinoma, over 20% of the patients will develop distant metastases. Our aim was to develop an easy-to-use prognostic model for predicting metastasis-free survival after radical or partial nephrectomy of
Externí odkaz:
https://doaj.org/article/f097036ba65447a59e243f07da006031
Publikováno v:
Radiation Oncology, Vol 13, Iss 1, Pp 1-11 (2018)
Abstract Background Cells in solid tumours are variably hypoxic and hence resistant to radiotherapy - the essential role of oxygen in the efficiency of irradiation has been acknowledged for decades. However, the currently available methods for perfor
Externí odkaz:
https://doaj.org/article/6ea51b107ef541d4b4b8b022d2044a8b
Autor:
Petra Miikkulainen, Heidi Högel, Krista Rantanen, Tomi Suomi, Petri Kouvonen, Laura L. Elo, Panu M. Jaakkola
Publikováno v:
Cancer & Metabolism, Vol 5, Iss 1, Pp 1-17 (2017)
Abstract Background A key feature of clear cell renal cell carcinoma (ccRCC) is the inactivation of the von Hippel-Lindau tumour suppressor protein (pVHL) that leads to the activation of hypoxia-inducible factor (HIF) pathway also in well-oxygenated
Externí odkaz:
https://doaj.org/article/653e76bfcb16431caf12436de93d5e7a
Autor:
Panu M. Jaakkola, Veli-Matti Kähäri, Reidar Grenman, Terhi Jokilehto, Marika Nummela, Pekka T. Heikkinen
Supplementary Figures 1-8 from Hypoxic Conversion of SMAD7 Function from an Inhibitor into a Promoter of Cell Invasion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c1333cebdde82da9cc99875636badf0
https://doi.org/10.1158/0008-5472.22382622
https://doi.org/10.1158/0008-5472.22382622
Autor:
Panu M. Jaakkola, Veli-Matti Kähäri, Reidar Grenman, Terhi Jokilehto, Marika Nummela, Pekka T. Heikkinen
Supplementary Figure Legends 1-8 from Hypoxic Conversion of SMAD7 Function from an Inhibitor into a Promoter of Cell Invasion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66aa97c9094d1828d52d85565932a56e
https://doi.org/10.1158/0008-5472.22382625.v1
https://doi.org/10.1158/0008-5472.22382625.v1
Autor:
Panu M. Jaakkola, Veli-Matti Kähäri, Reidar Grenman, Terhi Jokilehto, Marika Nummela, Pekka T. Heikkinen
Smad7 is an inhibitor of the transforming growth factor-β–activated signaling pathway. Under well-oxygenated conditions, Smad7 is a potent inhibitor of carcinoma cell invasion. Paradoxically, however, the expression of Smad7 is upregulated across
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a352aaaf90d13cc9d502c441b83cda5
https://doi.org/10.1158/0008-5472.c.6500265
https://doi.org/10.1158/0008-5472.c.6500265
Autor:
Panu M. Jaakkola, Veli-Matti Kähäri, Reidar Grenman, Terhi Jokilehto, Marika Nummela, Pekka T. Heikkinen
Supplementary Table 1 from Hypoxic Conversion of SMAD7 Function from an Inhibitor into a Promoter of Cell Invasion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b736386fa51b2c8a8d1e8e247bca9a7
https://doi.org/10.1158/0008-5472.22382616
https://doi.org/10.1158/0008-5472.22382616
Publikováno v:
Cancers, Vol 14, Iss 239, p 239 (2022)
Approximately 20% of patients with renal cell carcinoma (RCC) present with primarily metastatic disease and over 30% of patients with localized RCC will develop distant metastases later, after complete resection of the primary tumor. Accurate postope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::23229eb671193277506c6dd06a365dc8
https://www.mdpi.com/2072-6694/14/1/239
https://www.mdpi.com/2072-6694/14/1/239
Publikováno v:
Cancers
Simple Summary Approximately one fifth of patients with newly diagnosed renal cell carcinoma (RCC) present with metastatic disease and over one third of the remaining patients with localized RCC will eventually have metastases spread to distant sites
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::adab796f8e7f08ada49d1c58adad6318
https://pubmed.ncbi.nlm.nih.gov/35008402
https://pubmed.ncbi.nlm.nih.gov/35008402